Monthly information on share capital and company voting rights
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS) reports a total number of 71,751,201 shares in the capital and 77,686,109 voting rights as of November 30, 2023. For further information, please contact Media Chief of Staff Patricia Sosa Navarro at +33 (0)7 76 77 46 93 or media@cellectis.com, and Investor Relations Chief Business Officer Arthur Stril at +1 (347) 809 5980 or investors@cellectis.com.
Positive
- None.
Negative
- None.
Insights
Analyzing...
(Article 223-16 of General Regulation of the French financial markets authority)
PARIS, Dec. 01, 2023 (GLOBE NEWSWIRE) --
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total number of shares in the capital | Total number of voting rights |
| 11/30/2023 | 71,751,201 | 77,686,109 |
For further information on Cellectis, please contact:
Media contact:
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com
Investor Relations contacts:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577
Attachment
FAQ
What is the total number of shares in the capital for Cellectis as of November 30, 2023?
Cellectis reports a total number of 71,751,201 shares in the capital.
How many voting rights does Cellectis have as of November 30, 2023?
Cellectis reports a total of 77,686,109 voting rights as of November 30, 2023.
Who can be contacted for media inquiries at Cellectis?
For media inquiries, please contact Patricia Sosa Navarro, Chief of Staff to the CEO, at +33 (0)7 76 77 46 93 or media@cellectis.com.
Who can be contacted for investor relations at Cellectis?
For investor relations, please contact Arthur Stril, Chief Business Officer, at +1 (347) 809 5980 or investors@cellectis.com.
Cellectis